Manufacturing Plants

Established in 1935, the Starogard Gdański site is the historical heart of the Polpharma Group and one of the most advanced pharmaceutical manufacturing facilities in Europe. With decades of expertise and continuous investment, it remains central to the Group’s industrial operations in Poland. Following its privatization in 2000, the site has expanded through extensive modernization, including major upgrades in solid oral and parenteral manufacturing. In 2001, a new production building for solid oral dosage forms was commissioned, significantly increasing capacity and enabling the use of advanced manufacturing technologies

To further enhance sterile manufacturing capabilities, a new ampoule production facility was launched in 2005. This addition expanded the site's parenteral operations, which now include two sterile production areas: polyethylene containers produced via blow-fill-seal technology, and glass ampoules. The site is also home to the only facility in Poland producing active pharmaceutical ingredients (APIs) on an industrial scale. In 2024, Polpharma further expanded its API capabilities with the launch of a new high-potency API (HPAPI) facility — reinforcing the plant’s strategic role in the development and production of complex and specialized substances for the Group and external partners.